Shanghai Sunway Biotech Co., Ltd is a high-tech company in Shanghaiwhich is dedicated to cancer gene therapy for improving QOL of cancer patients, and health care. The headquarter is located in Shanghai Pudong Jinqiao Biotechnology Industrial Park.

​

The company was established in 1995 and has developed rapidlly through two major fundings in 1999 and 2003.

​

The main products under developing are oncolytic viruses -H100 series for cancer therapy. Three genetic engineering adenoviruses have been developed successfully with intellectual properties,which are called H101, H102, and H103.

​

H101 (Recombinant Human Adenovirus Type 5 Injection; Brand name: Oncorine®) : on market since September, 2006.

H103 (Oncolytic Recombinant Adenovirus Injection): phase I clinical trial finished.

H102: preclinical Stage.

​

The company has filed a total of 12 patents including Chinese patents, international patents (PCT) and American patents through developing H100 series products. Among those, nine Chinese patents and one Japanese patent have been granted.
 

Introduction of oncorine

Oncorine (Recombinant Human Adenovirus Type 5 Injection) is the first oncolytic virus drug which was approved in the world and independent intellectual property is hold by the company. After oncorine was listed on national 863 plan and SME Innovation Foundation of Science and Technology Ministry in 2000, it had been listed on “the 10th five-year plan” of major science and technology projects for national “863” plan in 2002. It was adopted as project of Shanghai New and High-tech Achievements Transformation in 2004. Oncorine was got NDA of national calss I biological products in October, 2005. Offical formal manufacture approval was got in April, 2006. And it was successful on the market since September in the same year.

​

ONCORINE- Recombinant Human Adenovirus Type 5 Injection
Introduction of the Sunway Biotech